AbCellera Biologics (ABCL) Receivables (2020 - 2026)

AbCellera Biologics has reported Receivables for 7 years, with the latest figure at $39.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 38.43% year-over-year to $39.2 million; the trailing twelve-month figure through Mar 2026 stood at $39.2 million (down 38.43% YoY), and the FY2025 full-year result was $58.3 million, up 73.41% from the prior year.
• Receivables for Q1 2026 stood at $39.2 million, down from $58.3 million in the prior quarter.
• The five-year high for Receivables was $334.4 million in Q1 2022, with the low at $9.3 million in Q4 2022.
• Historically, Receivables has averaged $63.2 million across 5 years, with a median of $39.2 million in 2026.
• Annual changes were most pronounced in 2022 — Receivables tumbled 94.21% — and 2023, when it jumped 228.92%.
• AbCellera Biologics' Receivables stood at $9.3 million in 2022, then jumped by 228.92% to $30.6 million in 2023, then grew by 9.89% to $33.6 million in 2024, then surged by 73.41% to $58.3 million in 2025, then plunged by 32.82% to $39.2 million in 2026.
• The last three Receivables figures came in at $39.2 million (Q1 2026), $58.3 million (Q4 2025), and $71.2 million (Q3 2025), per Business Quant data.